Communicating contraceptive effectiveness: A randomized controlled trial to inform a World Health Organization family planning handbook - 18/08/11
, James Trussell, PhD b, Neha Mehta, MPH a, Sean Condon, DrPH a, Sumathi Subramaniam, MPH c, Deborah Bourne, MA d
Reprint requests: Markus Steiner, PhD, Family Health International, PO Box 13950, Research Triangle Park, NC 27709.Abstract |
Objective |
The objective of the study was to compare 3 different approaches for increasing clients’ understanding of contraceptive effectiveness.
Study design |
We randomized 900 reproductive-age women in India and Jamaica to 1 of 3 charts presenting pregnancy risk.
Results |
The most important reason for choosing a contraceptive was how well it prevents pregnancy (54%) followed by few side effects (17%). At baseline, knowledge about contraceptive effectiveness was poor. About half knew oral contraceptive pills are more effective than condoms (46%) and intrauterine devices are more effective than injectables (50%). All 3 charts improved knowledge significantly (P < .01) for these 2 questions. No chart improved knowledge better than any other (P > .05). The chart ranking contraceptive methods on a continuum was judged slightly easier to understand than the other 2 charts.
Conclusion |
Only with accurate understanding of pregnancy risk can clients make informed choices. Our results have already informed a global handbook for family planning providers to use the chart ranking contraceptive methods on a continuum.
Le texte complet de cet article est disponible en PDF.Key words : Contraception, Contraceptive counseling, Informed choice, Decision aids
Plan
| Supported by the William and Flora Hewlett Foundation. |
Vol 195 - N° 1
P. 85-91 - juillet 2006 Retour au numéro
Article précédent
- Impact of an adolescent sex education program that was implemented by an academic medical center
- Patricia J. Sulak, Sara J. Herbelin, Dee Dee A. Fix, Thomas J. Kuehl
- Long-term safety of an extended-cycle oral contraceptive (Seasonale): A 2-year multicenter open-label extension trial
- F.D. Anderson, William Gibbons, David Portman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?